Macular edema is the condition when the fluid and proteins start collecting on or under the macula of the eye thereby resulting in swelling. Due to such swelling, a person’s central eye vision gets distorted. Macular edema is classified into two types namely cystoids macular edema (CME) and diabetic macular edema (DME).
Diabetic macular edema is the major reason for loss of vision in patients suffering from diabetic retinopathy. Diabetes patient are reported to have a 10% risk of developing this condition during their lifetime. On the basis of the cause of disease, DME is classified into two types:
- Diffuse macular edema: due to abnormalities in dilated capillaries present in the retina.
- Focal macular edema: due to abnormalities in microaneurysms
For diagnosing diabetic macular edema, an ophthalmologist checks the retina for symptoms of the disease including leaking blood vessel, retinal swelling, damaged nerve tissues and pale, fatty deposits on the retina. For further confirmation, comprehensive eye examination such as visual acuity test, dilated exam test and tonometry are performed.
During the initial stages of DME, no treatment is needed unless the patients efficiently control their blood sugar levels. If the condition becomes severe, the standard treatment for diabetic macular edema is laser photocoagulation. This procedure utilizes laser to reduce edema byapplying a pattern of burnsor bycauterizing leaky blood vessels. For avoiding the side-effects of this treatment, retinal specialists apply injections of anti-vascular endothelial growth factorcorticosteroids along with laser photocoagulation. Currently, there are only two approved drugs available in market for treating DME namely Lucentis and Ozurdex. Other treatment methods are currently under clinical trials.
The markets for America and Europe are at the maturity stage for diabetic macular edema because large proportion of population is suffering from diabetes. Lucentis and Ozurdex ocuppy the major part of the market share in the therapeutics market. Asia-Pacific is also growing at faster pace while the markets of Africa and Australia are currently at initial stages. Some of the companies and institutes which are involved in clinical trials for treatment of diabetic macular edema are Allergan, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., Pfizer, Inc.,Bayer AG, Bausch & Lomb Incorporated,the Diabetic Retinopathy Clinical Research Network, The National Eye Institute, Johns Hopkins University and ShahidBeheshti University of Medical Sciences.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.